Abstract
Uveitis refers to approximately 25 different diseases all characterized by the presence of intraocular inflammation. The uveitides are a relatively uncommon group of diseases, with an estimated incidence in the United States of 17–54/100,000/year and prevalence of 115–204/100,000 population. Nevertheless, because uveitis affects all ages, and in many cases is a lifelong disease, it has a disproportionate effect on years of potential vision lost and is the fifth or sixth leading cause of blindness in the United States. Because it is relatively uncommon, much of the information on uveitis comes from retrospective case series rather than from prospective epidemiologic studies or randomized clinical trials. Although these case series may provide the best data available, they are subject to several limitations, which must be understood in order to interpret the information properly.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Begg C, Cho M, Eastwood S et al (1996) Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 276:637–639
Bykhovskaya I, Thorne JE, Kempen JH, Dunn JP, Jabs DA (2005) Vogt-Koyanagi-Harada disease: clinical outcomes. Am J Ophthalmol 140:674–678
Darrell RW, Wagener HP, Kurland LT (1962) Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch Ophthalmol 68:502–514
DiLoreto DA Jr, Bressler NM, Bressler SB et al (2003) Use of best and final visual acuity outcomes in ophthalmological research. Arch Ophthalmol 121:1586–1590
Foster CS, Alter G, DeBarge LR et al (1996) Efficacy and safety of rimexolone 1 % ophthalmic suspension vs 1 % prednisolone acetate in the treatment of uveitis. Am J Ophthalmol 122:171–182
Gritz DC, Wong IG (2004) Incidence and prevalence of uveitis in northern California. The Northern California Epidemiology of Uveitis Study. Ophthalmology 111:491–500
Jabs DA (1995) Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc 93:623–683
Jabs DA (2005) Improving the reporting of clinical case series. Am J Ophthalmol 139:900–905
Jabs DA (2008) Epidemiology of uveitis. Ophthalmic Epidemiol 15:283–284
Jabs DA, Nussenblatt RB, Rosenbaum JT et al (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140:509–516
Kempen JH, Daniel E, Dunn JP et al (2009) Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive the-rapy: retrospective cohort study. Brit Med J 339:b2480
Kempen JH, Daniel E, Gangaputra S et al (2008) Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol 15:47–55
Kempen JH, Ganesh SK, Sangwan VS et al (2008) Interobserver agreement in grading activity and site of inflammation in eyes of patients with uveitis. Am J Ophthalmol 146:813–818
Lalezari JP, Stagg RJ, Kuppermann BD et al (1997) Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 126:257–263
Loteprednol Etabonate US Uveitis Study Group (1999) Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am J Ophthalmol 127:537–544
Martin DF, Kuppermann BD, Wolitz RA et al (1999) Oral ganciclovir for patients with cytomegalovirus retinitis treated with ganciclovir implant. Roche ganciclovir study group. N Engl J Med 340:1063–1070
Martin DF, Parks DJ, Mellaw SD et al (1994) Treatment of CMV retinitis with an intraocular sustained-release gancyclovir implant: A randomized controlled clinical trial. Arch Ophthalmol 112:1531–1539
Martin DF, Sierra-Madero J, for the Valganciclovir Study Group et al (2002) A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 346:1119–1126
Masuda K, Nakajima A, Urayama A et al (1989) Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet 1:1093–1096
McCannel CA, Holland GN, Helm CJ et al (1996) Causes of uveitis in the general practice of ophthalmology. Am J Ophthalmol 121:35–46
Meinert CL (1986) Clinical trials: design, conduct, and analysis. Oxford University Press, New York
Multicenter Uveitis Steroid Treatment Trial (MUST) (2008) Protocol Version 3.3. Multicenter Uveitis Steroid Treatment Trial (MUST). http://www.musttrial.org/. Accessed 11 Dec 2008
Murphy CC, Greiner K, Plskova J et al (2005) Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 123:634–641
Musch DC, Martin DF, for The Ganciclovir Implant Study Group et al (1997) Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med 337:83–90
Nussenblatt RB (1990) The natural history of uveitis. Int Ophthalmol 14:303–308
Nussenblatt RB, Palestine AG, Chan CC et al (1991) Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endo-genous uveitis. Am J Ophthalmol 112:138–146
Nussenblatt RB, Palestine AG, Chan CC, Roberge F (1985) Standardization of Vitreal Inflammatory Activity in Intermediate and Posterior Uveitis. Ophthalmology 92:467
Palestine AG, Polis MA, De Smet MD et al (1991) A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 115:665–673
Rosenbaum JT, Holland GH (1996) Uveitis and the Tower of Babel. Arch Ophthalmol 114:604–605
Schachat AP, Chambers WA, Liesegang TJ et al (2003) Safe and effective. Ophthalmology 110:2073–2074
Silveira C, Belfort R Jr, Muccioli C et al (2002) The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol 134:41–46
Spector SA, Weingeist T, Pollard RB et al (1993) A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group. J Infect Dis 168:557–563
STROBE Initiative (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 147:573–577
Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trial Group (1996) Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: the Cytomegalovirus Retreatment Trial. Arch Ophthalmol 114:23–33
Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trial Group (1997) Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC Peripheral Cytomegalovirus Retinitis Trial. A rando-mized, controlled trial. Ann Intern Med 126:264–274
Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group (1992) Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 326:213–220
Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group (1994) Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Ophthalmology 101:1250–1261
Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group (1997) MSL-109 adjuvant therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the Monoclonal Antibody Cytomegalovirus Retinitis Trials Group. Arch Ophthalmol 115:1528–1536
Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group (2001) The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. Am J Ophthalmol 131:457–467
Teoh SC, Hogan AC, Dick AD et al (2008) Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol 146:752–760
Thorne JE, Jabs DA, Kedhar SR et al (2008) Loss of visual field among patients with birdshot chorioretinopathy. Am J Ophthalmol 145:23–28
Thorne JE, Jabs DA, Peters GB et al (2005) Birdshot retinochoroidopathy: Ocular complications and visual impairment. Am J Ophthalmol 140:45–51
Thorne JE, Jabs DA, Qazi FA et al (2005) Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 112:1472–1477
Thorne JE, Wittenberg S, Jabs DA et al (2006) Multifocal choroiditis with panuveitis – Incidence of ocular complications and loss of visual acuity. Ophthalmology 113:2310–2316
Yazici H, Pazarli H, Barnes CG et al (1990) A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med 322:281–285
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Jabs, D.A. (2016). Uveitis and Clinical Trials. In: Zierhut, M., Pavesio, C., Ohno, S., Orefice, F., Rao, N. (eds) Intraocular Inflammation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-75387-2_7
Download citation
DOI: https://doi.org/10.1007/978-3-540-75387-2_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-75385-8
Online ISBN: 978-3-540-75387-2
eBook Packages: MedicineMedicine (R0)